NCP 2.0 Repeat Study

NeuroCatch

Status: Completed

Conditions: Brain Health

Treatments: Device: NeuroCatch Platform

Study type: Interventional

Funder types: Industry

Identifiers

NCT04661592

NCI_NCClin_004

Details and patient eligibility

About

The NeuroCatch Platform™ version 2.0 (NCP2.0), an investigational medical device system developed by NeuroCatch Inc., consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP; brain response to a stimulus) information.

The purpose of the study is to understand how reliable and repeatable the ERP metrics elicited by the NCP platform are within participants over multiple sessions.

Full description

A new method for creating stimulus sequences was developed for NeuroCatch™ Platform 2.0. Rather than using a set of fixed, predetermined sequences to elicit ERPs this new method draws on a database of candidate word stimuli to generate a different, random stimulus sequence each time a scan is carried out. The goal of this is to reduce habituation to the stimulus sequences which is hypothesized to improve the repeatability of the component measurements. Characterizing how individuals respond to the stimulus sequences is an important step in the validation of the generation method itself. Understanding the degree of variability and prototypical values of each ERP component is crucial to the understanding of typical brain functioning. For this type of technology to be clinically viable in quantifying brain health, the investigators must first quantify the degree to which a healthy brain naturally fluctuates in it processing capability. This study is being carried out to assess how repeatable the ERPs elicited by the new method are while also considering the impact of intraindividual variability observed in previous investigations. Thus, by comparing the results of the scans over time, an assessment of the reliability of the new stimulus sequences can be made.

Enrollment: 36 patients

Sex: All

Ages: 19+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Any sex, at least 19 years of age or older
2. Able to understand the informed consent form, study procedures and willing to participate in study
3. Able to remain seated and focused for 7 minutes
4. In good health with no history of clinically relevant neurological illness or injury in the last 5 years

Exclusion criteria

1. Requires the use of hearing aids or a cochlear implant, diagnosed with tinnitus that is currently active, or has temporary damage to earing (e.g. punctured ear drum). Or unable to detect a 740Hz tone played at 85dB in both ears.
2. Implanted pacemaker or implanted electrical stimulators
3. Metal or plastic implants in the skull, excluding dental/facial implants
4. Exposed to an investigational drug or device 30 days prior to start in this study, or concurrent or planned use of investigational drug or device while enrolled in this study
5. Not proficient in English language
6. Diagnosed epilepsy or history of seizures
7. If female and of child-bearing potential: pregnant, suspected or planning to become pregnant or breast-feeding
8. Unhealthy scalp (apparent open wounds and/or bruised or weakened skin)

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

36 participants in 1 patient group

Control

Experimental group

Description:

Neurologically healthy individuals will be recruited for the longitudinal study

Treatment:

Device: NeuroCatch Platform